Overview of anti-vegf treatment regimens and new agents in age-related macular degeneration


Irgat S. G. , Divarci S. Y. , Doǧan M., Özçura F.

Retina-Vitreus, vol.30, no.2, pp.212-222, 2021 (Refereed Journals of Other Institutions) identifier

  • Publication Type: Article / Review
  • Volume: 30 Issue: 2
  • Publication Date: 2021
  • Doi Number: 10.37845/ret.vit.2021.30.38
  • Title of Journal : Retina-Vitreus
  • Page Numbers: pp.212-222
  • Keywords: Age-related macular degeneration, Bevacizumab, Ranibizumab and afl ibercept

Abstract

© 2021 Gazi Eye Foundation. All rights reserved.Age-related macular degeneration (AMD), which can result in central vision loss, is among the leading causes of blindness worldwide. The beginning of the anti-vascular endothelial growth factor (anti-VEGF) era has revolutionized the treatment of AMD. The effi cacy of anti-VEGFs (bevacizumab, ranibizumab and afl ibercept) has been proven in important clinical studies such as ANCHOR, MARINA and VIEW, leading to the widespread use of these agents in the treatment of AMD. This review focuses on important clinical studies using 3 anti-VEGF agents and their link with real-world evidence including data point specifi c to our country. Also, the effi cacy of anti-VEGF agents and real-life treatment regimens will be reviewed. New treatments under development in the search for the ideal agent for AMD treatment will also be discussed.